{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 1. Subscribe to the model package"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "To subscribe to the model package:\n",
    "1. Open the model package listing page <font color='red'> For Seller to update:[Title_of_your_product](Provide link to your marketplace listing of your product).</font>\n",
    "1. On the AWS Marketplace listing, click on the **Continue to subscribe** button.\n",
    "1. On the **Subscribe to this software** page, review and click on **\"Accept Offer\"** if you and your organization agrees with EULA, pricing, and support terms. \n",
    "1. Once you click on **Continue to configuration button** and then choose a **region**, you will see a **Product Arn** displayed. This is the model package ARN that you need to specify while creating a deployable model using Boto3. Copy the ARN corresponding to your region and specify the same in the following cell."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Biomarker Detection and Classification Pipeline\n",
    "\n",
    "\n",
    "- **Model**: `en.explain_doc.clinical_biomarker.pipeline`\n",
    "- **Model Description**: The specialized biomarker pipeline extracts biomarker entities, classifies sentences to identify the presence of biomarker entities, and establishes relations between the extracted entities from clinical documents.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "model_package_arn = \"<Customer to specify Model package ARN corresponding to their AWS region>\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "sagemaker.config INFO - Not applying SDK defaults from location: /etc/xdg/sagemaker/config.yaml\n",
      "sagemaker.config INFO - Not applying SDK defaults from location: /home/ec2-user/.config/sagemaker/config.yaml\n"
     ]
    }
   ],
   "source": [
    "import base64\n",
    "import json\n",
    "import uuid\n",
    "from sagemaker import ModelPackage\n",
    "import sagemaker as sage\n",
    "from sagemaker import get_execution_role\n",
    "import boto3\n",
    "from IPython.display import Image, display\n",
    "from PIL import Image as ImageEdit\n",
    "import numpy as np"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "sagemaker_session = sage.Session()\n",
    "s3_bucket = sagemaker_session.default_bucket()\n",
    "region = sagemaker_session.boto_region_name\n",
    "account_id = boto3.client(\"sts\").get_caller_identity().get(\"Account\")\n",
    "role = get_execution_role()\n",
    "\n",
    "sagemaker = boto3.client(\"sagemaker\")\n",
    "s3_client = sagemaker_session.boto_session.client(\"s3\")\n",
    "ecr = boto3.client(\"ecr\")\n",
    "sm_runtime = boto3.client(\"sagemaker-runtime\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 2. Create an endpoint and perform real-time inference"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "If you want to understand how real-time inference with Amazon SageMaker works, see [Documentation](https://docs.aws.amazon.com/sagemaker/latest/dg/how-it-works-hosting.html)."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "model_name = \"en-explain-doc-clinical-biomarker-pipeline\"\n",
    "\n",
    "real_time_inference_instance_type = \"ml.m4.xlarge\"\n",
    "batch_transform_inference_instance_type = \"ml.m4.xlarge\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### A. Create an endpoint"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "--------!"
     ]
    }
   ],
   "source": [
    "# create a deployable model from the model package.\n",
    "model = ModelPackage(\n",
    "    role=role, model_package_arn=model_package_arn, sagemaker_session=sagemaker_session\n",
    ")\n",
    "\n",
    "# Deploy the model\n",
    "predictor = model.deploy(1, real_time_inference_instance_type, endpoint_name=model_name)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Once endpoint has been created, you would be able to perform real-time inference."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "import json\n",
    "import pandas as pd\n",
    "import os\n",
    "import boto3\n",
    "\n",
    "# Set display options\n",
    "pd.set_option('display.max_rows', None)\n",
    "pd.set_option('display.max_columns', None)\n",
    "pd.set_option('display.max_colwidth', None)\n",
    "\n",
    "def process_data_and_invoke_realtime_endpoint(data, content_type, accept):\n",
    "\n",
    "    content_type_to_format = {'application/json': 'json', 'application/jsonlines': 'jsonl'}\n",
    "    input_format = content_type_to_format.get(content_type)\n",
    "    if content_type not in content_type_to_format.keys() or accept not in content_type_to_format.keys():\n",
    "        raise ValueError(\"Invalid content_type or accept. It should be either 'application/json' or 'application/jsonlines'.\")\n",
    "\n",
    "    i = 1\n",
    "    input_dir = f'inputs/real-time/{input_format}'\n",
    "    output_dir = f'outputs/real-time/{input_format}'\n",
    "    s3_input_dir = f\"{model_name}/validation-input/real-time/{input_format}\"\n",
    "    s3_output_dir = f\"{model_name}/validation-output/real-time/{input_format}\"\n",
    "\n",
    "    input_file_name = f'{input_dir}/input{i}.{input_format}'\n",
    "    output_file_name = f'{output_dir}/{os.path.basename(input_file_name)}.out'\n",
    "\n",
    "    while os.path.exists(input_file_name) or os.path.exists(output_file_name):\n",
    "        i += 1\n",
    "        input_file_name = f'{input_dir}/input{i}.{input_format}'\n",
    "        output_file_name = f'{output_dir}/{os.path.basename(input_file_name)}.out'\n",
    "\n",
    "    os.makedirs(os.path.dirname(input_file_name), exist_ok=True)\n",
    "    os.makedirs(os.path.dirname(output_file_name), exist_ok=True)\n",
    "\n",
    "    input_data = json.dumps(data) if content_type == 'application/json' else data\n",
    "\n",
    "    # Write input data to file\n",
    "    with open(input_file_name, 'w') as f:\n",
    "        f.write(input_data)\n",
    "\n",
    "    # Upload input data to S3\n",
    "    s3_client.put_object(Bucket=s3_bucket, Key=f\"{s3_input_dir}/{os.path.basename(input_file_name)}\", Body=bytes(input_data.encode('UTF-8')))\n",
    "\n",
    "    # Invoke the SageMaker endpoint\n",
    "    response = sm_runtime.invoke_endpoint(\n",
    "        EndpointName=model_name,\n",
    "        ContentType=content_type,\n",
    "        Accept=accept,\n",
    "        Body=input_data,\n",
    "    )\n",
    "\n",
    "    # Read response data\n",
    "    response_data = json.loads(response[\"Body\"].read().decode(\"utf-8\")) if accept == 'application/json' else response['Body'].read().decode('utf-8')\n",
    "\n",
    "    # Save response data to file\n",
    "    with open(output_file_name, 'w') as f_out:\n",
    "        if accept == 'application/json':\n",
    "            json.dump(response_data, f_out, indent=4)\n",
    "        else:\n",
    "            for item in response_data.split('\\n'):\n",
    "                f_out.write(item + '\\n')\n",
    "\n",
    "    # Upload response data to S3\n",
    "    output_s3_key = f\"{s3_output_dir}/{os.path.basename(output_file_name)}\"\n",
    "    if accept == 'application/json':\n",
    "        s3_client.put_object(Bucket=s3_bucket, Key=output_s3_key, Body=json.dumps(response_data).encode('UTF-8'))\n",
    "    else:\n",
    "        s3_client.put_object(Bucket=s3_bucket, Key=output_s3_key, Body=response_data)\n",
    "\n",
    "    return response_data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Initial Setup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "docs = [\n",
    "        \"\"\"The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.\"\"\",\n",
    "\n",
    "        \"\"\"The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).\"\"\"\n",
    "]\n",
    "\n",
    "sample_text = \"\"\"In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.\"\"\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### JSON"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Example 1"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "  **Input format**:\n",
    "  \n",
    "  \n",
    "```json\n",
    "{\n",
    "    \"text\": \"Single text document\"\n",
    "}\n",
    "```"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "input_json_data = {\"text\": sample_text}\n",
    "\n",
    "data =  process_data_and_invoke_realtime_endpoint(input_json_data, content_type=\"application/json\" , accept=\"application/json\" )\n",
    "ner_df = pd.DataFrame(data[\"ner_predictions\"])\n",
    "relation_df = pd.DataFrame(data[\"relation_predictions\"])\n",
    "classification_df = pd.DataFrame(data[\"classification_predictions\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>document</th>\n",
       "      <th>ner_chunk</th>\n",
       "      <th>begin</th>\n",
       "      <th>end</th>\n",
       "      <th>ner_label</th>\n",
       "      <th>ner_confidence</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>positive</td>\n",
       "      <td>84</td>\n",
       "      <td>91</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.9672</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>CD9</td>\n",
       "      <td>97</td>\n",
       "      <td>99</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.992</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>CD10</td>\n",
       "      <td>105</td>\n",
       "      <td>108</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.9987</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>tumor markers</td>\n",
       "      <td>151</td>\n",
       "      <td>163</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.48290002</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>elevated level</td>\n",
       "      <td>172</td>\n",
       "      <td>185</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.90779996</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>Cyfra21-1</td>\n",
       "      <td>190</td>\n",
       "      <td>198</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.9851</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>4.77 ng/mL</td>\n",
       "      <td>201</td>\n",
       "      <td>210</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.9719</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>NSE</td>\n",
       "      <td>213</td>\n",
       "      <td>215</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.9991</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>19.60 ng/mL</td>\n",
       "      <td>218</td>\n",
       "      <td>228</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.96005</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>SCCA</td>\n",
       "      <td>235</td>\n",
       "      <td>238</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.9979</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>2.58 ng/mL</td>\n",
       "      <td>241</td>\n",
       "      <td>250</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.96169996</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>positive</td>\n",
       "      <td>289</td>\n",
       "      <td>296</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.9986</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>CK5/6</td>\n",
       "      <td>311</td>\n",
       "      <td>315</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.9995</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>P40</td>\n",
       "      <td>318</td>\n",
       "      <td>320</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.9978</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>negative</td>\n",
       "      <td>327</td>\n",
       "      <td>334</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.9987</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>TTF-1</td>\n",
       "      <td>349</td>\n",
       "      <td>353</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.9969</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>weakly positive staining</td>\n",
       "      <td>359</td>\n",
       "      <td>382</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.7521667</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>ALK</td>\n",
       "      <td>388</td>\n",
       "      <td>390</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.9947</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                                                                                                                                                                                    document  \\\n",
       "0   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "1   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "2   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "3   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "4   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "5   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "6   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "7   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "8   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "9   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "10  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "11  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "12  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "13  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "14  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "15  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "16  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "17  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "\n",
       "                   ner_chunk  begin  end         ner_label ner_confidence  \n",
       "0                   positive     84   91  Biomarker_Result         0.9672  \n",
       "1                        CD9     97   99         Biomarker          0.992  \n",
       "2                       CD10    105  108         Biomarker         0.9987  \n",
       "3              tumor markers    151  163         Biomarker     0.48290002  \n",
       "4             elevated level    172  185  Biomarker_Result     0.90779996  \n",
       "5                  Cyfra21-1    190  198         Biomarker         0.9851  \n",
       "6                 4.77 ng/mL    201  210  Biomarker_Result         0.9719  \n",
       "7                        NSE    213  215         Biomarker         0.9991  \n",
       "8                19.60 ng/mL    218  228  Biomarker_Result        0.96005  \n",
       "9                       SCCA    235  238         Biomarker         0.9979  \n",
       "10                2.58 ng/mL    241  250  Biomarker_Result     0.96169996  \n",
       "11                  positive    289  296  Biomarker_Result         0.9986  \n",
       "12                     CK5/6    311  315         Biomarker         0.9995  \n",
       "13                       P40    318  320         Biomarker         0.9978  \n",
       "14                  negative    327  334  Biomarker_Result         0.9987  \n",
       "15                     TTF-1    349  353         Biomarker         0.9969  \n",
       "16  weakly positive staining    359  382  Biomarker_Result      0.7521667  \n",
       "17                       ALK    388  390         Biomarker         0.9947  "
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ner_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>document</th>\n",
       "      <th>ner_chunk1</th>\n",
       "      <th>ner_chunk1_begin</th>\n",
       "      <th>ner_chunk1_end</th>\n",
       "      <th>ner_label1</th>\n",
       "      <th>ner_chunk2</th>\n",
       "      <th>ner_chunk2_begin</th>\n",
       "      <th>ner_chunk2_end</th>\n",
       "      <th>ner_label2</th>\n",
       "      <th>relation</th>\n",
       "      <th>relation_confidence</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>positive</td>\n",
       "      <td>84</td>\n",
       "      <td>91</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>CD9</td>\n",
       "      <td>97</td>\n",
       "      <td>99</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.9932805</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>positive</td>\n",
       "      <td>84</td>\n",
       "      <td>91</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>CD10</td>\n",
       "      <td>105</td>\n",
       "      <td>108</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.9988914</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>tumor markers</td>\n",
       "      <td>151</td>\n",
       "      <td>163</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>elevated level</td>\n",
       "      <td>172</td>\n",
       "      <td>185</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.90050846</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>tumor markers</td>\n",
       "      <td>151</td>\n",
       "      <td>163</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>4.77 ng/mL</td>\n",
       "      <td>201</td>\n",
       "      <td>210</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>O</td>\n",
       "      <td>0.7407979</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>tumor markers</td>\n",
       "      <td>151</td>\n",
       "      <td>163</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>19.60 ng/mL</td>\n",
       "      <td>218</td>\n",
       "      <td>228</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>O</td>\n",
       "      <td>0.9778502</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>tumor markers</td>\n",
       "      <td>151</td>\n",
       "      <td>163</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>2.58 ng/mL</td>\n",
       "      <td>241</td>\n",
       "      <td>250</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>O</td>\n",
       "      <td>0.9993332</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>elevated level</td>\n",
       "      <td>172</td>\n",
       "      <td>185</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>Cyfra21-1</td>\n",
       "      <td>190</td>\n",
       "      <td>198</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.9950375</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>elevated level</td>\n",
       "      <td>172</td>\n",
       "      <td>185</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>NSE</td>\n",
       "      <td>213</td>\n",
       "      <td>215</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>O</td>\n",
       "      <td>0.81141526</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>elevated level</td>\n",
       "      <td>172</td>\n",
       "      <td>185</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>SCCA</td>\n",
       "      <td>235</td>\n",
       "      <td>238</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>O</td>\n",
       "      <td>0.9064728</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>Cyfra21-1</td>\n",
       "      <td>190</td>\n",
       "      <td>198</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>4.77 ng/mL</td>\n",
       "      <td>201</td>\n",
       "      <td>210</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.9818734</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>Cyfra21-1</td>\n",
       "      <td>190</td>\n",
       "      <td>198</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>19.60 ng/mL</td>\n",
       "      <td>218</td>\n",
       "      <td>228</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.54173946</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>Cyfra21-1</td>\n",
       "      <td>190</td>\n",
       "      <td>198</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>2.58 ng/mL</td>\n",
       "      <td>241</td>\n",
       "      <td>250</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>O</td>\n",
       "      <td>0.952869</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>4.77 ng/mL</td>\n",
       "      <td>201</td>\n",
       "      <td>210</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>NSE</td>\n",
       "      <td>213</td>\n",
       "      <td>215</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>O</td>\n",
       "      <td>0.9998766</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>4.77 ng/mL</td>\n",
       "      <td>201</td>\n",
       "      <td>210</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>SCCA</td>\n",
       "      <td>235</td>\n",
       "      <td>238</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>O</td>\n",
       "      <td>0.9999279</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>NSE</td>\n",
       "      <td>213</td>\n",
       "      <td>215</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>19.60 ng/mL</td>\n",
       "      <td>218</td>\n",
       "      <td>228</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.9881728</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>NSE</td>\n",
       "      <td>213</td>\n",
       "      <td>215</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>2.58 ng/mL</td>\n",
       "      <td>241</td>\n",
       "      <td>250</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>O</td>\n",
       "      <td>0.98150694</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>19.60 ng/mL</td>\n",
       "      <td>218</td>\n",
       "      <td>228</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>SCCA</td>\n",
       "      <td>235</td>\n",
       "      <td>238</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>O</td>\n",
       "      <td>0.99992144</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>SCCA</td>\n",
       "      <td>235</td>\n",
       "      <td>238</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>2.58 ng/mL</td>\n",
       "      <td>241</td>\n",
       "      <td>250</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.9957568</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>positive</td>\n",
       "      <td>289</td>\n",
       "      <td>296</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>CK5/6</td>\n",
       "      <td>311</td>\n",
       "      <td>315</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.8663684</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>positive</td>\n",
       "      <td>289</td>\n",
       "      <td>296</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>P40</td>\n",
       "      <td>318</td>\n",
       "      <td>320</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.8959994</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>positive</td>\n",
       "      <td>289</td>\n",
       "      <td>296</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>TTF-1</td>\n",
       "      <td>349</td>\n",
       "      <td>353</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>O</td>\n",
       "      <td>0.9821239</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>positive</td>\n",
       "      <td>289</td>\n",
       "      <td>296</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>ALK</td>\n",
       "      <td>388</td>\n",
       "      <td>390</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>O</td>\n",
       "      <td>0.99950695</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>CK5/6</td>\n",
       "      <td>311</td>\n",
       "      <td>315</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>negative</td>\n",
       "      <td>327</td>\n",
       "      <td>334</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>O</td>\n",
       "      <td>0.9834041</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>CK5/6</td>\n",
       "      <td>311</td>\n",
       "      <td>315</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>weakly positive staining</td>\n",
       "      <td>359</td>\n",
       "      <td>382</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>O</td>\n",
       "      <td>0.999496</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>P40</td>\n",
       "      <td>318</td>\n",
       "      <td>320</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>negative</td>\n",
       "      <td>327</td>\n",
       "      <td>334</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>O</td>\n",
       "      <td>0.9339211</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>P40</td>\n",
       "      <td>318</td>\n",
       "      <td>320</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>weakly positive staining</td>\n",
       "      <td>359</td>\n",
       "      <td>382</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>O</td>\n",
       "      <td>0.9994236</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>negative</td>\n",
       "      <td>327</td>\n",
       "      <td>334</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>TTF-1</td>\n",
       "      <td>349</td>\n",
       "      <td>353</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.99416393</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>negative</td>\n",
       "      <td>327</td>\n",
       "      <td>334</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>ALK</td>\n",
       "      <td>388</td>\n",
       "      <td>390</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>O</td>\n",
       "      <td>0.85932535</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>TTF-1</td>\n",
       "      <td>349</td>\n",
       "      <td>353</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>weakly positive staining</td>\n",
       "      <td>359</td>\n",
       "      <td>382</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>O</td>\n",
       "      <td>0.9996277</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>weakly positive staining</td>\n",
       "      <td>359</td>\n",
       "      <td>382</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>ALK</td>\n",
       "      <td>388</td>\n",
       "      <td>390</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.98843086</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                                                                                                                                                                                    document  \\\n",
       "0   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "1   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "2   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "3   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "4   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "5   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "6   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "7   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "8   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "9   In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "10  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "11  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "12  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "13  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "14  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "15  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "16  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "17  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "18  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "19  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "20  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "21  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "22  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "23  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "24  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "25  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "26  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "27  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "28  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "29  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "\n",
       "                  ner_chunk1 ner_chunk1_begin ner_chunk1_end  \\\n",
       "0                   positive               84             91   \n",
       "1                   positive               84             91   \n",
       "2              tumor markers              151            163   \n",
       "3              tumor markers              151            163   \n",
       "4              tumor markers              151            163   \n",
       "5              tumor markers              151            163   \n",
       "6             elevated level              172            185   \n",
       "7             elevated level              172            185   \n",
       "8             elevated level              172            185   \n",
       "9                  Cyfra21-1              190            198   \n",
       "10                 Cyfra21-1              190            198   \n",
       "11                 Cyfra21-1              190            198   \n",
       "12                4.77 ng/mL              201            210   \n",
       "13                4.77 ng/mL              201            210   \n",
       "14                       NSE              213            215   \n",
       "15                       NSE              213            215   \n",
       "16               19.60 ng/mL              218            228   \n",
       "17                      SCCA              235            238   \n",
       "18                  positive              289            296   \n",
       "19                  positive              289            296   \n",
       "20                  positive              289            296   \n",
       "21                  positive              289            296   \n",
       "22                     CK5/6              311            315   \n",
       "23                     CK5/6              311            315   \n",
       "24                       P40              318            320   \n",
       "25                       P40              318            320   \n",
       "26                  negative              327            334   \n",
       "27                  negative              327            334   \n",
       "28                     TTF-1              349            353   \n",
       "29  weakly positive staining              359            382   \n",
       "\n",
       "          ner_label1                ner_chunk2 ner_chunk2_begin  \\\n",
       "0   Biomarker_Result                       CD9               97   \n",
       "1   Biomarker_Result                      CD10              105   \n",
       "2          Biomarker            elevated level              172   \n",
       "3          Biomarker                4.77 ng/mL              201   \n",
       "4          Biomarker               19.60 ng/mL              218   \n",
       "5          Biomarker                2.58 ng/mL              241   \n",
       "6   Biomarker_Result                 Cyfra21-1              190   \n",
       "7   Biomarker_Result                       NSE              213   \n",
       "8   Biomarker_Result                      SCCA              235   \n",
       "9          Biomarker                4.77 ng/mL              201   \n",
       "10         Biomarker               19.60 ng/mL              218   \n",
       "11         Biomarker                2.58 ng/mL              241   \n",
       "12  Biomarker_Result                       NSE              213   \n",
       "13  Biomarker_Result                      SCCA              235   \n",
       "14         Biomarker               19.60 ng/mL              218   \n",
       "15         Biomarker                2.58 ng/mL              241   \n",
       "16  Biomarker_Result                      SCCA              235   \n",
       "17         Biomarker                2.58 ng/mL              241   \n",
       "18  Biomarker_Result                     CK5/6              311   \n",
       "19  Biomarker_Result                       P40              318   \n",
       "20  Biomarker_Result                     TTF-1              349   \n",
       "21  Biomarker_Result                       ALK              388   \n",
       "22         Biomarker                  negative              327   \n",
       "23         Biomarker  weakly positive staining              359   \n",
       "24         Biomarker                  negative              327   \n",
       "25         Biomarker  weakly positive staining              359   \n",
       "26  Biomarker_Result                     TTF-1              349   \n",
       "27  Biomarker_Result                       ALK              388   \n",
       "28         Biomarker  weakly positive staining              359   \n",
       "29  Biomarker_Result                       ALK              388   \n",
       "\n",
       "   ner_chunk2_end        ner_label2       relation relation_confidence  \n",
       "0              99         Biomarker  is_finding_of           0.9932805  \n",
       "1             108         Biomarker  is_finding_of           0.9988914  \n",
       "2             185  Biomarker_Result  is_finding_of          0.90050846  \n",
       "3             210  Biomarker_Result              O           0.7407979  \n",
       "4             228  Biomarker_Result              O           0.9778502  \n",
       "5             250  Biomarker_Result              O           0.9993332  \n",
       "6             198         Biomarker  is_finding_of           0.9950375  \n",
       "7             215         Biomarker              O          0.81141526  \n",
       "8             238         Biomarker              O           0.9064728  \n",
       "9             210  Biomarker_Result  is_finding_of           0.9818734  \n",
       "10            228  Biomarker_Result  is_finding_of          0.54173946  \n",
       "11            250  Biomarker_Result              O            0.952869  \n",
       "12            215         Biomarker              O           0.9998766  \n",
       "13            238         Biomarker              O           0.9999279  \n",
       "14            228  Biomarker_Result  is_finding_of           0.9881728  \n",
       "15            250  Biomarker_Result              O          0.98150694  \n",
       "16            238         Biomarker              O          0.99992144  \n",
       "17            250  Biomarker_Result  is_finding_of           0.9957568  \n",
       "18            315         Biomarker  is_finding_of           0.8663684  \n",
       "19            320         Biomarker  is_finding_of           0.8959994  \n",
       "20            353         Biomarker              O           0.9821239  \n",
       "21            390         Biomarker              O          0.99950695  \n",
       "22            334  Biomarker_Result              O           0.9834041  \n",
       "23            382  Biomarker_Result              O            0.999496  \n",
       "24            334  Biomarker_Result              O           0.9339211  \n",
       "25            382  Biomarker_Result              O           0.9994236  \n",
       "26            353         Biomarker  is_finding_of          0.99416393  \n",
       "27            390         Biomarker              O          0.85932535  \n",
       "28            382  Biomarker_Result              O           0.9996277  \n",
       "29            390         Biomarker  is_finding_of          0.98843086  "
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "relation_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>document</th>\n",
       "      <th>sentence</th>\n",
       "      <th>begin</th>\n",
       "      <th>end</th>\n",
       "      <th>class</th>\n",
       "      <th>class_confidence</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry.</td>\n",
       "      <td>0</td>\n",
       "      <td>127</td>\n",
       "      <td>1</td>\n",
       "      <td>0.99894834</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL.</td>\n",
       "      <td>129</td>\n",
       "      <td>251</td>\n",
       "      <td>1</td>\n",
       "      <td>0.99983305</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.</td>\n",
       "      <td>253</td>\n",
       "      <td>391</td>\n",
       "      <td>1</td>\n",
       "      <td>0.999121</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                                                                                                                                                                                   document  \\\n",
       "0  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "1  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "2  In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry. Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL. Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "\n",
       "                                                                                                                                      sentence  \\\n",
       "0             In the bone- marrow (BM) aspiration, blasts accounted for 88.1% of ANCs, which were positive for CD9 and CD10 on flow cytometry.   \n",
       "1                  Measurements of serum tumor markers showed elevated level of Cyfra21-1: 4.77 ng/mL, NSE: 19.60 ng/mL, and SCCA: 2.58 ng/mL.   \n",
       "2  Immunohistochemical staining showed positive staining for CK5/6, P40, and negative staining for TTF-1 and weakly positive staining for ALK.   \n",
       "\n",
       "   begin  end class class_confidence  \n",
       "0      0  127     1       0.99894834  \n",
       "1    129  251     1       0.99983305  \n",
       "2    253  391     1         0.999121  "
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "classification_df"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Example 2"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "  **Input format**:\n",
    "  \n",
    "  \n",
    "```json\n",
    "{\n",
    "    \"text\": [\n",
    "        \"Text document 1\",\n",
    "        \"Text document 2\",\n",
    "        ...\n",
    "    ]\n",
    "}\n",
    "```"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "input_json_data = {\"text\": docs}\n",
    "\n",
    "data =  process_data_and_invoke_realtime_endpoint(input_json_data, content_type=\"application/json\" , accept=\"application/json\" )\n",
    "ner_df = pd.DataFrame(data[\"ner_predictions\"])\n",
    "relation_df = pd.DataFrame(data[\"relation_predictions\"])\n",
    "classification_df = pd.DataFrame(data[\"classification_predictions\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>document</th>\n",
       "      <th>ner_chunk</th>\n",
       "      <th>begin</th>\n",
       "      <th>end</th>\n",
       "      <th>ner_label</th>\n",
       "      <th>ner_confidence</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>mutation</td>\n",
       "      <td>30</td>\n",
       "      <td>37</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.7702</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>42</td>\n",
       "      <td>45</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>exon 21 (L858R</td>\n",
       "      <td>47</td>\n",
       "      <td>60</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.778375</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>EGFR-KDD</td>\n",
       "      <td>90</td>\n",
       "      <td>97</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.5694</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>cyclin-dependent kinase gene</td>\n",
       "      <td>145</td>\n",
       "      <td>172</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.35023332</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>mutation</td>\n",
       "      <td>180</td>\n",
       "      <td>187</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.7639</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>SMARCA4 gene</td>\n",
       "      <td>196</td>\n",
       "      <td>207</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.7303</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>alpha-fetoprotein</td>\n",
       "      <td>177</td>\n",
       "      <td>193</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.9951</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>AFP</td>\n",
       "      <td>196</td>\n",
       "      <td>198</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.995</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>normal</td>\n",
       "      <td>211</td>\n",
       "      <td>216</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.8999</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>2.2 ng/mL</td>\n",
       "      <td>222</td>\n",
       "      <td>230</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.9585</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                     document  \\\n",
       "0      The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "1      The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "2      The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "3      The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "4      The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "5      The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "6      The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "7   The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "8   The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "9   The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "10  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "\n",
       "                       ner_chunk  begin  end         ner_label ner_confidence  \n",
       "0                       mutation     30   37  Biomarker_Result         0.7702  \n",
       "1                           EGFR     42   45         Biomarker           None  \n",
       "2                 exon 21 (L858R     47   60  Biomarker_Result       0.778375  \n",
       "3                       EGFR-KDD     90   97         Biomarker         0.5694  \n",
       "4   cyclin-dependent kinase gene    145  172         Biomarker     0.35023332  \n",
       "5                       mutation    180  187  Biomarker_Result         0.7639  \n",
       "6                   SMARCA4 gene    196  207         Biomarker         0.7303  \n",
       "7              alpha-fetoprotein    177  193         Biomarker         0.9951  \n",
       "8                            AFP    196  198         Biomarker          0.995  \n",
       "9                         normal    211  216  Biomarker_Result         0.8999  \n",
       "10                     2.2 ng/mL    222  230  Biomarker_Result         0.9585  "
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ner_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>document</th>\n",
       "      <th>ner_chunk1</th>\n",
       "      <th>ner_chunk1_begin</th>\n",
       "      <th>ner_chunk1_end</th>\n",
       "      <th>ner_label1</th>\n",
       "      <th>ner_chunk2</th>\n",
       "      <th>ner_chunk2_begin</th>\n",
       "      <th>ner_chunk2_end</th>\n",
       "      <th>ner_label2</th>\n",
       "      <th>relation</th>\n",
       "      <th>relation_confidence</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>mutation</td>\n",
       "      <td>30</td>\n",
       "      <td>37</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>42</td>\n",
       "      <td>45</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.9997267</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>mutation</td>\n",
       "      <td>30</td>\n",
       "      <td>37</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>EGFR-KDD</td>\n",
       "      <td>90</td>\n",
       "      <td>97</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.76452106</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>42</td>\n",
       "      <td>45</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>exon 21 (L858R</td>\n",
       "      <td>47</td>\n",
       "      <td>60</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.99678254</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>exon 21 (L858R</td>\n",
       "      <td>47</td>\n",
       "      <td>60</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>EGFR-KDD</td>\n",
       "      <td>90</td>\n",
       "      <td>97</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>O</td>\n",
       "      <td>0.8720176</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>cyclin-dependent kinase gene</td>\n",
       "      <td>145</td>\n",
       "      <td>172</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>mutation</td>\n",
       "      <td>180</td>\n",
       "      <td>187</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>O</td>\n",
       "      <td>0.7650012</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>mutation</td>\n",
       "      <td>180</td>\n",
       "      <td>187</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>SMARCA4 gene</td>\n",
       "      <td>196</td>\n",
       "      <td>207</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.9763348</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>alpha-fetoprotein</td>\n",
       "      <td>177</td>\n",
       "      <td>193</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>normal</td>\n",
       "      <td>211</td>\n",
       "      <td>216</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.9780766</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>alpha-fetoprotein</td>\n",
       "      <td>177</td>\n",
       "      <td>193</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>2.2 ng/mL</td>\n",
       "      <td>222</td>\n",
       "      <td>230</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.8552585</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>AFP</td>\n",
       "      <td>196</td>\n",
       "      <td>198</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>normal</td>\n",
       "      <td>211</td>\n",
       "      <td>216</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.9946333</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>AFP</td>\n",
       "      <td>196</td>\n",
       "      <td>198</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>2.2 ng/mL</td>\n",
       "      <td>222</td>\n",
       "      <td>230</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.97450024</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                    document  \\\n",
       "0     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "1     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "2     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "3     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "4     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "5     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "6  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "7  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "8  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "9  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "\n",
       "                     ner_chunk1 ner_chunk1_begin ner_chunk1_end  \\\n",
       "0                      mutation               30             37   \n",
       "1                      mutation               30             37   \n",
       "2                          EGFR               42             45   \n",
       "3                exon 21 (L858R               47             60   \n",
       "4  cyclin-dependent kinase gene              145            172   \n",
       "5                      mutation              180            187   \n",
       "6             alpha-fetoprotein              177            193   \n",
       "7             alpha-fetoprotein              177            193   \n",
       "8                           AFP              196            198   \n",
       "9                           AFP              196            198   \n",
       "\n",
       "         ner_label1      ner_chunk2 ner_chunk2_begin ner_chunk2_end  \\\n",
       "0  Biomarker_Result            EGFR               42             45   \n",
       "1  Biomarker_Result        EGFR-KDD               90             97   \n",
       "2         Biomarker  exon 21 (L858R               47             60   \n",
       "3  Biomarker_Result        EGFR-KDD               90             97   \n",
       "4         Biomarker        mutation              180            187   \n",
       "5  Biomarker_Result    SMARCA4 gene              196            207   \n",
       "6         Biomarker          normal              211            216   \n",
       "7         Biomarker       2.2 ng/mL              222            230   \n",
       "8         Biomarker          normal              211            216   \n",
       "9         Biomarker       2.2 ng/mL              222            230   \n",
       "\n",
       "         ner_label2       relation relation_confidence  \n",
       "0         Biomarker  is_finding_of           0.9997267  \n",
       "1         Biomarker  is_finding_of          0.76452106  \n",
       "2  Biomarker_Result  is_finding_of          0.99678254  \n",
       "3         Biomarker              O           0.8720176  \n",
       "4  Biomarker_Result              O           0.7650012  \n",
       "5         Biomarker  is_finding_of           0.9763348  \n",
       "6  Biomarker_Result  is_finding_of           0.9780766  \n",
       "7  Biomarker_Result  is_finding_of           0.8552585  \n",
       "8  Biomarker_Result  is_finding_of           0.9946333  \n",
       "9  Biomarker_Result  is_finding_of          0.97450024  "
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "relation_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>document</th>\n",
       "      <th>sentence</th>\n",
       "      <th>begin</th>\n",
       "      <th>end</th>\n",
       "      <th>class</th>\n",
       "      <th>class_confidence</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified.</td>\n",
       "      <td>0</td>\n",
       "      <td>122</td>\n",
       "      <td>0</td>\n",
       "      <td>0.99996203</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>124</td>\n",
       "      <td>229</td>\n",
       "      <td>0</td>\n",
       "      <td>0.99990267</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites.</td>\n",
       "      <td>0</td>\n",
       "      <td>72</td>\n",
       "      <td>0</td>\n",
       "      <td>0.9999781</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions.</td>\n",
       "      <td>74</td>\n",
       "      <td>171</td>\n",
       "      <td>0</td>\n",
       "      <td>0.999972</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>173</td>\n",
       "      <td>232</td>\n",
       "      <td>1</td>\n",
       "      <td>0.99928665</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                    document  \\\n",
       "0     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "1     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "2  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "3  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "4  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "\n",
       "                                                                                                                      sentence  \\\n",
       "0  The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified.   \n",
       "1                   Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "2                                                    The ultrasonography revealed the patent's artificial vessels and ascites.   \n",
       "3                           The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions.   \n",
       "4                                                                 The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "\n",
       "   begin  end class class_confidence  \n",
       "0      0  122     0       0.99996203  \n",
       "1    124  229     0       0.99990267  \n",
       "2      0   72     0        0.9999781  \n",
       "3     74  171     0         0.999972  \n",
       "4    173  232     1       0.99928665  "
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "classification_df"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### JSON Lines"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "  **Input format**:\n",
    "  \n",
    "```json\n",
    "{\"text\": \"Text document 1\"}\n",
    "{\"text\": \"Text document 2\"}\n",
    "```"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "def create_jsonl(records):\n",
    "    json_records = []\n",
    "\n",
    "    for text in records:\n",
    "        record = {\n",
    "            \"text\": text\n",
    "        }\n",
    "        json_records.append(record)\n",
    "\n",
    "    json_lines = '\\n'.join(json.dumps(record) for record in json_records)\n",
    "\n",
    "    return json_lines\n",
    "\n",
    "input_jsonl_data = create_jsonl(docs)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Example 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\"ner_predictions\": [{\"ner_chunk\": \"mutation\", \"begin\": 30, \"end\": 37, \"ner_label\": \"Biomarker_Result\", \"ner_confidence\": \"0.7702\"}, {\"ner_chunk\": \"EGFR\", \"begin\": 42, \"end\": 45, \"ner_label\": \"Biomarker\", \"ner_confidence\": null}, {\"ner_chunk\": \"exon 21 (L858R\", \"begin\": 47, \"end\": 60, \"ner_label\": \"Biomarker_Result\", \"ner_confidence\": \"0.778375\"}, {\"ner_chunk\": \"EGFR-KDD\", \"begin\": 90, \"end\": 97, \"ner_label\": \"Biomarker\", \"ner_confidence\": \"0.5694\"}, {\"ner_chunk\": \"cyclin-dependent kinase gene\", \"begin\": 145, \"end\": 172, \"ner_label\": \"Biomarker\", \"ner_confidence\": \"0.35023332\"}, {\"ner_chunk\": \"mutation\", \"begin\": 180, \"end\": 187, \"ner_label\": \"Biomarker_Result\", \"ner_confidence\": \"0.7639\"}, {\"ner_chunk\": \"SMARCA4 gene\", \"begin\": 196, \"end\": 207, \"ner_label\": \"Biomarker\", \"ner_confidence\": \"0.7303\"}], \"relation_predictions\": [{\"ner_chunk1\": \"mutation\", \"ner_chunk1_begin\": \"30\", \"ner_chunk1_end\": \"37\", \"ner_label1\": \"Biomarker_Result\", \"ner_chunk2\": \"EGFR\", \"ner_chunk2_begin\": \"42\", \"ner_chunk2_end\": \"45\", \"ner_label2\": \"Biomarker\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.9997267\"}, {\"ner_chunk1\": \"mutation\", \"ner_chunk1_begin\": \"30\", \"ner_chunk1_end\": \"37\", \"ner_label1\": \"Biomarker_Result\", \"ner_chunk2\": \"EGFR-KDD\", \"ner_chunk2_begin\": \"90\", \"ner_chunk2_end\": \"97\", \"ner_label2\": \"Biomarker\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.76452106\"}, {\"ner_chunk1\": \"EGFR\", \"ner_chunk1_begin\": \"42\", \"ner_chunk1_end\": \"45\", \"ner_label1\": \"Biomarker\", \"ner_chunk2\": \"exon 21 (L858R\", \"ner_chunk2_begin\": \"47\", \"ner_chunk2_end\": \"60\", \"ner_label2\": \"Biomarker_Result\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.99678254\"}, {\"ner_chunk1\": \"exon 21 (L858R\", \"ner_chunk1_begin\": \"47\", \"ner_chunk1_end\": \"60\", \"ner_label1\": \"Biomarker_Result\", \"ner_chunk2\": \"EGFR-KDD\", \"ner_chunk2_begin\": \"90\", \"ner_chunk2_end\": \"97\", \"ner_label2\": \"Biomarker\", \"relation\": \"O\", \"relation_confidence\": \"0.8720176\"}, {\"ner_chunk1\": \"cyclin-dependent kinase gene\", \"ner_chunk1_begin\": \"145\", \"ner_chunk1_end\": \"172\", \"ner_label1\": \"Biomarker\", \"ner_chunk2\": \"mutation\", \"ner_chunk2_begin\": \"180\", \"ner_chunk2_end\": \"187\", \"ner_label2\": \"Biomarker_Result\", \"relation\": \"O\", \"relation_confidence\": \"0.7650012\"}, {\"ner_chunk1\": \"mutation\", \"ner_chunk1_begin\": \"180\", \"ner_chunk1_end\": \"187\", \"ner_label1\": \"Biomarker_Result\", \"ner_chunk2\": \"SMARCA4 gene\", \"ner_chunk2_begin\": \"196\", \"ner_chunk2_end\": \"207\", \"ner_label2\": \"Biomarker\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.9763348\"}], \"classification_predictions\": [{\"sentence\": \"The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified.\", \"begin\": 0, \"end\": 122, \"class\": \"0\", \"class_confidence\": \"0.99996203\"}, {\"sentence\": \"Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.\", \"begin\": 124, \"end\": 229, \"class\": \"0\", \"class_confidence\": \"0.99990267\"}]}\n",
      "{\"ner_predictions\": [{\"ner_chunk\": \"alpha-fetoprotein\", \"begin\": 177, \"end\": 193, \"ner_label\": \"Biomarker\", \"ner_confidence\": \"0.9951\"}, {\"ner_chunk\": \"AFP\", \"begin\": 196, \"end\": 198, \"ner_label\": \"Biomarker\", \"ner_confidence\": \"0.995\"}, {\"ner_chunk\": \"normal\", \"begin\": 211, \"end\": 216, \"ner_label\": \"Biomarker_Result\", \"ner_confidence\": \"0.8999\"}, {\"ner_chunk\": \"2.2 ng/mL\", \"begin\": 222, \"end\": 230, \"ner_label\": \"Biomarker_Result\", \"ner_confidence\": \"0.9585\"}], \"relation_predictions\": [{\"ner_chunk1\": \"alpha-fetoprotein\", \"ner_chunk1_begin\": \"177\", \"ner_chunk1_end\": \"193\", \"ner_label1\": \"Biomarker\", \"ner_chunk2\": \"normal\", \"ner_chunk2_begin\": \"211\", \"ner_chunk2_end\": \"216\", \"ner_label2\": \"Biomarker_Result\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.9780766\"}, {\"ner_chunk1\": \"alpha-fetoprotein\", \"ner_chunk1_begin\": \"177\", \"ner_chunk1_end\": \"193\", \"ner_label1\": \"Biomarker\", \"ner_chunk2\": \"2.2 ng/mL\", \"ner_chunk2_begin\": \"222\", \"ner_chunk2_end\": \"230\", \"ner_label2\": \"Biomarker_Result\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.8552585\"}, {\"ner_chunk1\": \"AFP\", \"ner_chunk1_begin\": \"196\", \"ner_chunk1_end\": \"198\", \"ner_label1\": \"Biomarker\", \"ner_chunk2\": \"normal\", \"ner_chunk2_begin\": \"211\", \"ner_chunk2_end\": \"216\", \"ner_label2\": \"Biomarker_Result\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.9946333\"}, {\"ner_chunk1\": \"AFP\", \"ner_chunk1_begin\": \"196\", \"ner_chunk1_end\": \"198\", \"ner_label1\": \"Biomarker\", \"ner_chunk2\": \"2.2 ng/mL\", \"ner_chunk2_begin\": \"222\", \"ner_chunk2_end\": \"230\", \"ner_label2\": \"Biomarker_Result\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.97450024\"}], \"classification_predictions\": [{\"sentence\": \"The ultrasonography revealed the patent's artificial vessels and ascites.\", \"begin\": 0, \"end\": 72, \"class\": \"0\", \"class_confidence\": \"0.9999781\"}, {\"sentence\": \"The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions.\", \"begin\": 74, \"end\": 171, \"class\": \"0\", \"class_confidence\": \"0.999972\"}, {\"sentence\": \"The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).\", \"begin\": 173, \"end\": 232, \"class\": \"1\", \"class_confidence\": \"0.99928665\"}]}\n"
     ]
    }
   ],
   "source": [
    "data = process_data_and_invoke_realtime_endpoint(input_jsonl_data, content_type=\"application/jsonlines\" , accept=\"application/jsonlines\" )\n",
    "print(data)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### C. Delete the endpoint"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Now that you have successfully performed a real-time inference, you do not need the endpoint any more. You can terminate the endpoint to avoid being charged."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "model.sagemaker_session.delete_endpoint(model_name)\n",
    "model.sagemaker_session.delete_endpoint_config(model_name)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "tags": []
   },
   "source": [
    "## 3. Batch inference"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "import json\n",
    "import os\n",
    "\n",
    "input_dir = 'inputs/batch'\n",
    "json_input_dir = f\"{input_dir}/json\"\n",
    "jsonl_input_dir = f\"{input_dir}/jsonl\"\n",
    "\n",
    "output_dir = 'outputs/batch'\n",
    "json_output_dir = f\"{output_dir}/json\"\n",
    "jsonl_output_dir = f\"{output_dir}/jsonl\"\n",
    "\n",
    "os.makedirs(json_input_dir, exist_ok=True)\n",
    "os.makedirs(jsonl_input_dir, exist_ok=True)\n",
    "os.makedirs(json_output_dir, exist_ok=True)\n",
    "os.makedirs(jsonl_output_dir, exist_ok=True)\n",
    "\n",
    "validation_json_file_name = \"input.json\"\n",
    "\n",
    "validation_jsonl_file_name = \"input.jsonl\"\n",
    "\n",
    "validation_input_json_path = f\"s3://{s3_bucket}/{model_name}/validation-input/batch/json/\"\n",
    "validation_output_json_path = f\"s3://{s3_bucket}/{model_name}/validation-output/batch/json/\"\n",
    "\n",
    "validation_input_jsonl_path = f\"s3://{s3_bucket}/{model_name}/validation-input/batch/jsonl/\"\n",
    "validation_output_jsonl_path = f\"s3://{s3_bucket}/{model_name}/validation-output/batch/jsonl/\"\n",
    "\n",
    "def write_and_upload_to_s3(input_data, file_name):\n",
    "    file_format = os.path.splitext(file_name)[1].lower()\n",
    "    if file_format == \".json\":\n",
    "        input_data = json.dumps(input_data)\n",
    "\n",
    "    with open(file_name, \"w\") as f:\n",
    "        f.write(input_data)\n",
    "\n",
    "    s3_client.put_object(\n",
    "        Bucket=s3_bucket,\n",
    "        Key=f\"{model_name}/validation-input/batch/{file_format[1:]}/{os.path.basename(file_name)}\",\n",
    "        Body=(bytes(input_data.encode(\"UTF-8\"))),\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "input_jsonl_data = create_jsonl(docs)\n",
    "input_json_data = {\"text\": docs}\n",
    "\n",
    "write_and_upload_to_s3(input_json_data, f\"{json_input_dir}/{validation_json_file_name}\")\n",
    "\n",
    "write_and_upload_to_s3(input_jsonl_data, f\"{jsonl_input_dir}/{validation_jsonl_file_name}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### JSON"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "# Initialize a SageMaker Transformer object for making predictions\n",
    "transformer = model.transformer(\n",
    "    instance_count=1,\n",
    "    instance_type=batch_transform_inference_instance_type,\n",
    "    accept=\"application/json\",\n",
    "    output_path=validation_output_json_path\n",
    ")\n",
    "\n",
    "transformer.transform(validation_input_json_path, content_type=\"application/json\")\n",
    "transformer.wait()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from urllib.parse import urlparse\n",
    "\n",
    "def process_s3_json_output_and_save(validation_file_name):\n",
    "\n",
    "    output_file_path = f\"{json_output_dir}/{validation_file_name}.out\"\n",
    "    parsed_url = urlparse(transformer.output_path)\n",
    "    file_key = f\"{parsed_url.path[1:]}{validation_file_name}.out\"\n",
    "    response = s3_client.get_object(Bucket=s3_bucket, Key=file_key)\n",
    "\n",
    "    data = json.loads(response[\"Body\"].read().decode(\"utf-8\"))\n",
    "    # Define a dictionary with DataFrame objects and their names\n",
    "    data_frames = {\n",
    "        \"NER Predictions DataFrame\": pd.DataFrame(data['ner_predictions']),\n",
    "        \"Relation Predictions DataFrame\": pd.DataFrame(data['relation_predictions']),\n",
    "        \"Classification Predictions DataFrame\": pd.DataFrame(data[\"classification_predictions\"])\n",
    "    }\n",
    "\n",
    "    # Display and save each DataFrame\n",
    "    for name, df in data_frames.items():\n",
    "        print(name + \":\")\n",
    "        display(df)\n",
    "    # Save the data to the output file\n",
    "    with open(output_file_path, 'w') as f_out:\n",
    "        json.dump(data, f_out, indent=4)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NER Predictions DataFrame:\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>document</th>\n",
       "      <th>ner_chunk</th>\n",
       "      <th>begin</th>\n",
       "      <th>end</th>\n",
       "      <th>ner_label</th>\n",
       "      <th>ner_confidence</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>mutation</td>\n",
       "      <td>30</td>\n",
       "      <td>37</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.7702</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>42</td>\n",
       "      <td>45</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>exon 21 (L858R</td>\n",
       "      <td>47</td>\n",
       "      <td>60</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.778375</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>EGFR-KDD</td>\n",
       "      <td>90</td>\n",
       "      <td>97</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.5694</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>cyclin-dependent kinase gene</td>\n",
       "      <td>145</td>\n",
       "      <td>172</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.35023332</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>mutation</td>\n",
       "      <td>180</td>\n",
       "      <td>187</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.7639</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>SMARCA4 gene</td>\n",
       "      <td>196</td>\n",
       "      <td>207</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.7303</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>alpha-fetoprotein</td>\n",
       "      <td>177</td>\n",
       "      <td>193</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.9951</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>AFP</td>\n",
       "      <td>196</td>\n",
       "      <td>198</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>0.995</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>normal</td>\n",
       "      <td>211</td>\n",
       "      <td>216</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.8999</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>2.2 ng/mL</td>\n",
       "      <td>222</td>\n",
       "      <td>230</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>0.9585</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                     document  \\\n",
       "0      The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "1      The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "2      The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "3      The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "4      The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "5      The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "6      The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "7   The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "8   The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "9   The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "10  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "\n",
       "                       ner_chunk  begin  end         ner_label ner_confidence  \n",
       "0                       mutation     30   37  Biomarker_Result         0.7702  \n",
       "1                           EGFR     42   45         Biomarker           None  \n",
       "2                 exon 21 (L858R     47   60  Biomarker_Result       0.778375  \n",
       "3                       EGFR-KDD     90   97         Biomarker         0.5694  \n",
       "4   cyclin-dependent kinase gene    145  172         Biomarker     0.35023332  \n",
       "5                       mutation    180  187  Biomarker_Result         0.7639  \n",
       "6                   SMARCA4 gene    196  207         Biomarker         0.7303  \n",
       "7              alpha-fetoprotein    177  193         Biomarker         0.9951  \n",
       "8                            AFP    196  198         Biomarker          0.995  \n",
       "9                         normal    211  216  Biomarker_Result         0.8999  \n",
       "10                     2.2 ng/mL    222  230  Biomarker_Result         0.9585  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Relation Predictions DataFrame:\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>document</th>\n",
       "      <th>ner_chunk1</th>\n",
       "      <th>ner_chunk1_begin</th>\n",
       "      <th>ner_chunk1_end</th>\n",
       "      <th>ner_label1</th>\n",
       "      <th>ner_chunk2</th>\n",
       "      <th>ner_chunk2_begin</th>\n",
       "      <th>ner_chunk2_end</th>\n",
       "      <th>ner_label2</th>\n",
       "      <th>relation</th>\n",
       "      <th>relation_confidence</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>mutation</td>\n",
       "      <td>30</td>\n",
       "      <td>37</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>42</td>\n",
       "      <td>45</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.9997267</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>mutation</td>\n",
       "      <td>30</td>\n",
       "      <td>37</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>EGFR-KDD</td>\n",
       "      <td>90</td>\n",
       "      <td>97</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.76452106</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>42</td>\n",
       "      <td>45</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>exon 21 (L858R</td>\n",
       "      <td>47</td>\n",
       "      <td>60</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.99678254</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>exon 21 (L858R</td>\n",
       "      <td>47</td>\n",
       "      <td>60</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>EGFR-KDD</td>\n",
       "      <td>90</td>\n",
       "      <td>97</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>O</td>\n",
       "      <td>0.8720176</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>cyclin-dependent kinase gene</td>\n",
       "      <td>145</td>\n",
       "      <td>172</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>mutation</td>\n",
       "      <td>180</td>\n",
       "      <td>187</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>O</td>\n",
       "      <td>0.7650012</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>mutation</td>\n",
       "      <td>180</td>\n",
       "      <td>187</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>SMARCA4 gene</td>\n",
       "      <td>196</td>\n",
       "      <td>207</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.9763348</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>alpha-fetoprotein</td>\n",
       "      <td>177</td>\n",
       "      <td>193</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>normal</td>\n",
       "      <td>211</td>\n",
       "      <td>216</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.9780766</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>alpha-fetoprotein</td>\n",
       "      <td>177</td>\n",
       "      <td>193</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>2.2 ng/mL</td>\n",
       "      <td>222</td>\n",
       "      <td>230</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.8552585</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>AFP</td>\n",
       "      <td>196</td>\n",
       "      <td>198</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>normal</td>\n",
       "      <td>211</td>\n",
       "      <td>216</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.9946333</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>AFP</td>\n",
       "      <td>196</td>\n",
       "      <td>198</td>\n",
       "      <td>Biomarker</td>\n",
       "      <td>2.2 ng/mL</td>\n",
       "      <td>222</td>\n",
       "      <td>230</td>\n",
       "      <td>Biomarker_Result</td>\n",
       "      <td>is_finding_of</td>\n",
       "      <td>0.97450024</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                    document  \\\n",
       "0     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "1     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "2     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "3     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "4     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "5     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "6  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "7  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "8  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "9  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "\n",
       "                     ner_chunk1 ner_chunk1_begin ner_chunk1_end  \\\n",
       "0                      mutation               30             37   \n",
       "1                      mutation               30             37   \n",
       "2                          EGFR               42             45   \n",
       "3                exon 21 (L858R               47             60   \n",
       "4  cyclin-dependent kinase gene              145            172   \n",
       "5                      mutation              180            187   \n",
       "6             alpha-fetoprotein              177            193   \n",
       "7             alpha-fetoprotein              177            193   \n",
       "8                           AFP              196            198   \n",
       "9                           AFP              196            198   \n",
       "\n",
       "         ner_label1      ner_chunk2 ner_chunk2_begin ner_chunk2_end  \\\n",
       "0  Biomarker_Result            EGFR               42             45   \n",
       "1  Biomarker_Result        EGFR-KDD               90             97   \n",
       "2         Biomarker  exon 21 (L858R               47             60   \n",
       "3  Biomarker_Result        EGFR-KDD               90             97   \n",
       "4         Biomarker        mutation              180            187   \n",
       "5  Biomarker_Result    SMARCA4 gene              196            207   \n",
       "6         Biomarker          normal              211            216   \n",
       "7         Biomarker       2.2 ng/mL              222            230   \n",
       "8         Biomarker          normal              211            216   \n",
       "9         Biomarker       2.2 ng/mL              222            230   \n",
       "\n",
       "         ner_label2       relation relation_confidence  \n",
       "0         Biomarker  is_finding_of           0.9997267  \n",
       "1         Biomarker  is_finding_of          0.76452106  \n",
       "2  Biomarker_Result  is_finding_of          0.99678254  \n",
       "3         Biomarker              O           0.8720176  \n",
       "4  Biomarker_Result              O           0.7650012  \n",
       "5         Biomarker  is_finding_of           0.9763348  \n",
       "6  Biomarker_Result  is_finding_of           0.9780766  \n",
       "7  Biomarker_Result  is_finding_of           0.8552585  \n",
       "8  Biomarker_Result  is_finding_of           0.9946333  \n",
       "9  Biomarker_Result  is_finding_of          0.97450024  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Classification Predictions DataFrame:\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>document</th>\n",
       "      <th>sentence</th>\n",
       "      <th>begin</th>\n",
       "      <th>end</th>\n",
       "      <th>class</th>\n",
       "      <th>class_confidence</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified.</td>\n",
       "      <td>0</td>\n",
       "      <td>122</td>\n",
       "      <td>0</td>\n",
       "      <td>0.99996203</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.</td>\n",
       "      <td>124</td>\n",
       "      <td>229</td>\n",
       "      <td>0</td>\n",
       "      <td>0.99990267</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites.</td>\n",
       "      <td>0</td>\n",
       "      <td>72</td>\n",
       "      <td>0</td>\n",
       "      <td>0.9999781</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions.</td>\n",
       "      <td>74</td>\n",
       "      <td>171</td>\n",
       "      <td>0</td>\n",
       "      <td>0.999972</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).</td>\n",
       "      <td>173</td>\n",
       "      <td>232</td>\n",
       "      <td>1</td>\n",
       "      <td>0.99928665</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                    document  \\\n",
       "0     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "1     The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified. Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "2  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "3  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "4  The ultrasonography revealed the patent's artificial vessels and ascites. The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions. The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "\n",
       "                                                                                                                      sentence  \\\n",
       "0  The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified.   \n",
       "1                   Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.   \n",
       "2                                                    The ultrasonography revealed the patent's artificial vessels and ascites.   \n",
       "3                           The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions.   \n",
       "4                                                                 The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).   \n",
       "\n",
       "   begin  end class class_confidence  \n",
       "0      0  122     0       0.99996203  \n",
       "1    124  229     0       0.99990267  \n",
       "2      0   72     0        0.9999781  \n",
       "3     74  171     0         0.999972  \n",
       "4    173  232     1       0.99928665  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "process_s3_json_output_and_save(validation_json_file_name)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### JSON Lines"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "transformer = model.transformer(\n",
    "    instance_count=1,\n",
    "    instance_type=batch_transform_inference_instance_type,\n",
    "    accept=\"application/jsonlines\",\n",
    "    output_path=validation_output_jsonl_path\n",
    ")\n",
    "transformer.transform(validation_input_jsonl_path, content_type=\"application/jsonlines\")\n",
    "transformer.wait()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "from urllib.parse import urlparse\n",
    "\n",
    "def process_s3_jsonlines_output_and_save(validation_file_name):\n",
    "\n",
    "    output_file_path = f\"{jsonl_output_dir}/{validation_file_name}.out\"\n",
    "    parsed_url = urlparse(transformer.output_path)\n",
    "    file_key = f\"{parsed_url.path[1:]}{validation_file_name}.out\"\n",
    "    response = s3_client.get_object(Bucket=s3_bucket, Key=file_key)\n",
    "\n",
    "    data = response[\"Body\"].read().decode(\"utf-8\")\n",
    "    print(data)\n",
    "\n",
    "    # Save the data to the output file\n",
    "    with open(output_file_path, 'w') as f_out:\n",
    "        for item in data.split('\\n'):\n",
    "            f_out.write(item + '\\n')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\"ner_predictions\": [{\"ner_chunk\": \"mutation\", \"begin\": 30, \"end\": 37, \"ner_label\": \"Biomarker_Result\", \"ner_confidence\": \"0.7702\"}, {\"ner_chunk\": \"EGFR\", \"begin\": 42, \"end\": 45, \"ner_label\": \"Biomarker\", \"ner_confidence\": null}, {\"ner_chunk\": \"exon 21 (L858R\", \"begin\": 47, \"end\": 60, \"ner_label\": \"Biomarker_Result\", \"ner_confidence\": \"0.778375\"}, {\"ner_chunk\": \"EGFR-KDD\", \"begin\": 90, \"end\": 97, \"ner_label\": \"Biomarker\", \"ner_confidence\": \"0.5694\"}, {\"ner_chunk\": \"cyclin-dependent kinase gene\", \"begin\": 145, \"end\": 172, \"ner_label\": \"Biomarker\", \"ner_confidence\": \"0.35023332\"}, {\"ner_chunk\": \"mutation\", \"begin\": 180, \"end\": 187, \"ner_label\": \"Biomarker_Result\", \"ner_confidence\": \"0.7639\"}, {\"ner_chunk\": \"SMARCA4 gene\", \"begin\": 196, \"end\": 207, \"ner_label\": \"Biomarker\", \"ner_confidence\": \"0.7303\"}], \"relation_predictions\": [{\"ner_chunk1\": \"mutation\", \"ner_chunk1_begin\": \"30\", \"ner_chunk1_end\": \"37\", \"ner_label1\": \"Biomarker_Result\", \"ner_chunk2\": \"EGFR\", \"ner_chunk2_begin\": \"42\", \"ner_chunk2_end\": \"45\", \"ner_label2\": \"Biomarker\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.9997267\"}, {\"ner_chunk1\": \"mutation\", \"ner_chunk1_begin\": \"30\", \"ner_chunk1_end\": \"37\", \"ner_label1\": \"Biomarker_Result\", \"ner_chunk2\": \"EGFR-KDD\", \"ner_chunk2_begin\": \"90\", \"ner_chunk2_end\": \"97\", \"ner_label2\": \"Biomarker\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.76452106\"}, {\"ner_chunk1\": \"EGFR\", \"ner_chunk1_begin\": \"42\", \"ner_chunk1_end\": \"45\", \"ner_label1\": \"Biomarker\", \"ner_chunk2\": \"exon 21 (L858R\", \"ner_chunk2_begin\": \"47\", \"ner_chunk2_end\": \"60\", \"ner_label2\": \"Biomarker_Result\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.99678254\"}, {\"ner_chunk1\": \"exon 21 (L858R\", \"ner_chunk1_begin\": \"47\", \"ner_chunk1_end\": \"60\", \"ner_label1\": \"Biomarker_Result\", \"ner_chunk2\": \"EGFR-KDD\", \"ner_chunk2_begin\": \"90\", \"ner_chunk2_end\": \"97\", \"ner_label2\": \"Biomarker\", \"relation\": \"O\", \"relation_confidence\": \"0.8720176\"}, {\"ner_chunk1\": \"cyclin-dependent kinase gene\", \"ner_chunk1_begin\": \"145\", \"ner_chunk1_end\": \"172\", \"ner_label1\": \"Biomarker\", \"ner_chunk2\": \"mutation\", \"ner_chunk2_begin\": \"180\", \"ner_chunk2_end\": \"187\", \"ner_label2\": \"Biomarker_Result\", \"relation\": \"O\", \"relation_confidence\": \"0.7650012\"}, {\"ner_chunk1\": \"mutation\", \"ner_chunk1_begin\": \"180\", \"ner_chunk1_end\": \"187\", \"ner_label1\": \"Biomarker_Result\", \"ner_chunk2\": \"SMARCA4 gene\", \"ner_chunk2_begin\": \"196\", \"ner_chunk2_end\": \"207\", \"ner_label2\": \"Biomarker\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.9763348\"}], \"classification_predictions\": [{\"sentence\": \"The results revealed that the mutation in EGFR exon 21 (L858R) had disappeared, and a new EGFR-KDD mutation was identified.\", \"begin\": 0, \"end\": 122, \"class\": \"0\", \"class_confidence\": \"0.99996203\"}, {\"sentence\": \"Amplification of the cyclin-dependent kinase gene and a mutation in the SMARCA4 gene were also identified.\", \"begin\": 124, \"end\": 229, \"class\": \"0\", \"class_confidence\": \"0.99990267\"}]}\n",
      "{\"ner_predictions\": [{\"ner_chunk\": \"alpha-fetoprotein\", \"begin\": 177, \"end\": 193, \"ner_label\": \"Biomarker\", \"ner_confidence\": \"0.9951\"}, {\"ner_chunk\": \"AFP\", \"begin\": 196, \"end\": 198, \"ner_label\": \"Biomarker\", \"ner_confidence\": \"0.995\"}, {\"ner_chunk\": \"normal\", \"begin\": 211, \"end\": 216, \"ner_label\": \"Biomarker_Result\", \"ner_confidence\": \"0.8999\"}, {\"ner_chunk\": \"2.2 ng/mL\", \"begin\": 222, \"end\": 230, \"ner_label\": \"Biomarker_Result\", \"ner_confidence\": \"0.9585\"}], \"relation_predictions\": [{\"ner_chunk1\": \"alpha-fetoprotein\", \"ner_chunk1_begin\": \"177\", \"ner_chunk1_end\": \"193\", \"ner_label1\": \"Biomarker\", \"ner_chunk2\": \"normal\", \"ner_chunk2_begin\": \"211\", \"ner_chunk2_end\": \"216\", \"ner_label2\": \"Biomarker_Result\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.9780766\"}, {\"ner_chunk1\": \"alpha-fetoprotein\", \"ner_chunk1_begin\": \"177\", \"ner_chunk1_end\": \"193\", \"ner_label1\": \"Biomarker\", \"ner_chunk2\": \"2.2 ng/mL\", \"ner_chunk2_begin\": \"222\", \"ner_chunk2_end\": \"230\", \"ner_label2\": \"Biomarker_Result\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.8552585\"}, {\"ner_chunk1\": \"AFP\", \"ner_chunk1_begin\": \"196\", \"ner_chunk1_end\": \"198\", \"ner_label1\": \"Biomarker\", \"ner_chunk2\": \"normal\", \"ner_chunk2_begin\": \"211\", \"ner_chunk2_end\": \"216\", \"ner_label2\": \"Biomarker_Result\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.9946333\"}, {\"ner_chunk1\": \"AFP\", \"ner_chunk1_begin\": \"196\", \"ner_chunk1_end\": \"198\", \"ner_label1\": \"Biomarker\", \"ner_chunk2\": \"2.2 ng/mL\", \"ner_chunk2_begin\": \"222\", \"ner_chunk2_end\": \"230\", \"ner_label2\": \"Biomarker_Result\", \"relation\": \"is_finding_of\", \"relation_confidence\": \"0.97450024\"}], \"classification_predictions\": [{\"sentence\": \"The ultrasonography revealed the patent's artificial vessels and ascites.\", \"begin\": 0, \"end\": 72, \"class\": \"0\", \"class_confidence\": \"0.9999781\"}, {\"sentence\": \"The contrast-enhanced computed tomography (CT) scan showed multiple, small, hypervascular lesions.\", \"begin\": 74, \"end\": 171, \"class\": \"0\", \"class_confidence\": \"0.999972\"}, {\"sentence\": \"The alpha-fetoprotein (AFP) level was normal (at 2.2 ng/mL).\", \"begin\": 173, \"end\": 232, \"class\": \"1\", \"class_confidence\": \"0.99928665\"}]}\n"
     ]
    }
   ],
   "source": [
    "process_s3_jsonlines_output_and_save(validation_jsonl_file_name)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:sagemaker:Deleting model with name: explain-clinical-doc-biomarker-2024-05-10-13-48-41-735\n"
     ]
    }
   ],
   "source": [
    "model.delete_model()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Unsubscribe to the listing (optional)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "tags": []
   },
   "source": [
    "If you would like to unsubscribe to the model package, follow these steps. Before you cancel the subscription, ensure that you do not have any [deployable model](https://console.aws.amazon.com/sagemaker/home#/models) created from the model package or using the algorithm. Note - You can find this information by looking at the container name associated with the model. \n",
    "\n",
    "**Steps to unsubscribe to product from AWS Marketplace**:\n",
    "1. Navigate to __Machine Learning__ tab on [__Your Software subscriptions page__](https://aws.amazon.com/marketplace/ai/library?productType=ml&ref_=mlmp_gitdemo_indust)\n",
    "2. Locate the listing that you want to cancel the subscription for, and then choose __Cancel Subscription__  to cancel the subscription.\n",
    "\n"
   ]
  }
 ],
 "metadata": {
  "instance_type": "ml.t3.medium",
  "kernelspec": {
   "display_name": "conda_python3",
   "language": "python",
   "name": "conda_python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
